

# **EXHIBIT G**

Page 1

1 UNITED STATES DISTRICT COURT

2 DISTRICT OF NEW JERSEY

3 CAMDEN VICINAGE

4

5 - - - - - x

6 IN RE:

7 VALSARTAN, LOSARTAN, MDL No. 2875

8 and IRBESARTAN PRODUCTS

9 LIABILITY LITIGATION

10 - - - - - x

11

12 PARTICIPANTS APPEARING VIA ZOOM

13

14 VIDEO DEPOSITION of DAVID MADIGAN, PhD

15 Thursday, August 5, 2021 - 9:32 a.m.

16

17

18

19 Reporter: Jill K. Ruggieri, RPR, RMR, FCRR, CRR

20

21

22

23

24

25

<p style="text-align: right;">Page 270</p> <p>1 A I did not.</p> <p>2 Q In connection with your work in 3 this case, did you find any studies that 4 suggest a statistically significant increased 5 risk of colorectal or intestinal cancer and 6 NDEA?</p> <p>7 A I did not.</p> <p>8 Q In connection with your work in 9 this case, did you read any studies or find 10 any studies suggesting a statistically 11 significant increased risk of gastric cancer 12 and NDEA?</p> <p>13 A I did not.</p> <p>14 Q In connection with your work in 15 this case, did you find any studies 16 suggesting a statistically significant 17 increased risk of kidney cancer and NDEA?</p> <p>18 A I did not.</p> <p>19 Q In connection with your work in 20 this case, did you find any study suggesting 21 a statistically significant increased risk of 22 liver cancer and NDEA?</p> <p>23 A I did not.</p> <p>24 Q In connection with your work in 25 this case, did you find any studies</p>	<p style="text-align: right;">Page 272</p> <p>1 significant risk of developing any form of 2 cancer other than pancreatic?</p> <p>3 A NDEA. I think you said "NDA."</p> <p>4 That's right. I don't have -- I don't have 5 studies that are germane to that question so 6 I can't answer the question.</p> <p>7 Q And just NDEA is what I was asking 8 about.</p> <p>9 A You said NDA.</p> <p>10 Q Not NDA, so thank you for 11 clarifying that.</p> <p>12 On page 6 of your report, 13 there it is, it's numbered paragraph 26.</p> <p>14 A Right.</p> <p>15 Q You sort of wrote in summary 16 fashion on the subject that you and I have 17 just been talking about.</p> <p>18 Your paragraph 26 reads:</p> <p>19 "Concerning NDEA, Zheng, et al., shows a 20 statistically significant increased risk and 21 an LCE of 2,520 micrograms," correct?</p> <p>22 A Correct.</p> <p>23 Q And "LCE" is an abbreviation for 24 "lifetime cumulative exposure."</p> <p>25 Is that right?</p>
<p style="text-align: right;">Page 271</p> <p>1 suggesting a statistically significant risk 2 of lung cancer and NDEA?</p> <p>3 A I did not.</p> <p>4 Q In connection with your work in 5 this case, did you find any studies 6 suggesting a statistically significant risk 7 of -- I'm going to butcher the 8 pronunciation -- pharyngeal cancer and NDEA?</p> <p>9 A I did not.</p> <p>10 Q In connection with your work in 11 this case, did you find any studies 12 suggesting a statistically significant risk 13 of prostate cancer and NDEA?</p> <p>14 A I did not.</p> <p>15 Q In connection with your work in 16 this case, did you find any study suggesting 17 a statistically significant increased risk of 18 uterine cancer and NDEA?</p> <p>19 A I did not.</p> <p>20 Q Based on the absence of any 21 observation studies relating to NDEA and any 22 form of cancer other than pancreatic, I take 23 it that you are not able to testify to any 24 reasonable degree of scientific certainty 25 that exposure to NDA creates statistically</p>	<p style="text-align: right;">Page 273</p> <p>1 A Right.</p> <p>2 Q And so what you write in your 3 report that you filed with the court in this 4 case -- which has been filed with the court 5 in this case is that there is a -- in your 6 opinion, a statistically significant 7 increased risk of pancreatic cancer where the 8 lifetime cumulative exposure of the NDEA is 9 greater than 2,520 micrograms?</p> <p>10 A Right.</p> <p>11 Q In doing the math, that would be 12 2,250,000 nanograms?</p> <p>13 A Two and a half million nanograms, 14 yes.</p> <p>15 Q Yes, 2,520,000 nanograms.</p> <p>16 I told you at the outset I 17 represent Mylan. I don't think you've 18 reviewed any Mylan company documents in 19 connection with your work in this case.</p> <p>20 Is that true?</p> <p>21 A I believe that's true.</p> <p>22 Q In your report, I didn't see any 23 reference to any Mylan company documents.</p> <p>24 Can we agree on that?</p> <p>25 A I believe that's correct. I</p>

<p>1 (Reporter interrupted.)</p> <p>2 A Sorry.</p> <p>3 Q I asked him. I can't even</p> <p>4 remember.</p> <p>5 I think what I asked you is do</p> <p>6 you intend to offer that opinion, and there</p> <p>7 was an objection to form, and then the</p> <p>8 witness was about to give an answer.</p> <p>9 A And the answer was I don't intend</p> <p>10 to, but if I was asked to, I would -- I could</p> <p>11 do that.</p> <p>12 Q Do you remember what exhibit that</p> <p>13 was that you looked at earlier this morning</p> <p>14 with the FDA numbers?</p> <p>15 A I think the first few exhibits, you</p> <p>16 took them back. Was it an early exhibit or</p> <p>17 was it later?</p> <p>18 Q It was early.</p> <p>19 A I have it. Let me check. Let me</p> <p>20 check I'm giving you the right thing. No,</p> <p>21 sorry, it's not the FDA one. It's the</p> <p>22 Torrent.</p> <p>23 Q Well, do you want to go off the</p> <p>24 record for a minute while we try to find the</p> <p>25 exhibit?</p>	<p>Page 278</p> <p>1 Q Correct.</p> <p>2 A Okay. So it would take -- at that</p> <p>3 level, it would take 6600 days to get to --</p> <p>4 if you're consuming .38 micrograms a day of</p> <p>5 Mylan -- of NDEA, it would take you 6,631</p> <p>6 days to get to 2500 -- an exposure --</p> <p>7 cumulative exposure of 2520, ignoring --</p> <p>8 ignoring NDEA from diet and other sources,</p> <p>9 just purely from that source.</p> <p>10 Q And that's -- and that</p> <p>11 2,520 micrograms is the LCE that you've</p> <p>12 calculated for there to be a statistically</p> <p>13 significant increase of pancreatic cancer?</p> <p>14 A That's --</p> <p>15 Q NDEA.</p> <p>16 A As the Zheng study would suggest,</p> <p>17 yes.</p> <p>18 Q Okay. Thank you for that.</p> <p>19 The -- and I guess just to</p> <p>20 sort of wrap it up from my perspective,</p> <p>21 Dr. Madigan, what I understood your testimony</p> <p>22 to be is that you are not going to offer any</p> <p>23 general causation opinions, correct?</p> <p>24 A Correct.</p> <p>25 Q What you are able to do and what --</p>
<p>1 I only have about ten more</p> <p>2 minutes of questions, I think.</p> <p>3 (Counsel conferred.)</p> <p>4 THE VIDEOGRAPHER: Are we</p> <p>5 going off the record?</p> <p>6 MS. LOCKARD: No, we have it.</p> <p>7 BY MR. TRISCHLER:</p> <p>8 Q So Ms. Lockard has been kind</p> <p>9 enough to provide us with a chart that we've</p> <p>10 been referencing, and you can see on page 2</p> <p>11 of that chart, there is some data that was</p> <p>12 provided with respect to Mylan.</p> <p>13 Do you see that?</p> <p>14 A I do.</p> <p>15 Q So if you wanted to do the</p> <p>16 calculation, let's take, for instance, the</p> <p>17 highest level for Mylan reported on that</p> <p>18 chart I think is .38 parts per million,</p> <p>19 correct?</p> <p>20 A In micrograms per tablet.</p> <p>21 Q Okay.</p> <p>22 And --</p> <p>23 A And the level that you were asking</p> <p>24 me about is -- the number in paragraph 35,</p> <p>25 2520.</p>	<p>Page 279</p> <p>1 the work that you did in this case was to</p> <p>2 perform a statistical analysis on the</p> <p>3 literature that was provided to you by</p> <p>4 Dr. Etminan, correct?</p> <p>5 A No.</p> <p>6 MR. NIGH: Objection.</p> <p>7 A So the -- this -- I was provided</p> <p>8 with a list by Dr. Etminan which was a seed</p> <p>9 list, if you will, so I consider lots of</p> <p>10 other potential materials.</p> <p>11 As it turns out, none of them,</p> <p>12 you know, the set of studies that are</p> <p>13 ultimately in Table 1 are the ones in</p> <p>14 Etminan, as it happens.</p> <p>15 Q So while you may have looked beyond</p> <p>16 what was originally given to you in the list</p> <p>17 created by Dr. Etminan, the studies that you</p> <p>18 have -- that you ultimately utilize for your</p> <p>19 statistical analysis are the same ones that</p> <p>20 he provided to you?</p> <p>21 A They were on his -- they're studies</p> <p>22 that are on the list of references in his</p> <p>23 report, as it happens.</p> <p>24 Q And just to make sure my feeble</p> <p>25 mind is able to understand it, what you're</p>